
Neumic Therapeutics Ltd
New Zealand · Biotech & life sciences · Undetermined

ZymoChem
United States · Biotech & life sciences · Series A
Compatibility /100
36/100
Medium potentialWhy talk
- Neumic Therapeutics Ltd likely needs funding — ZymoChem (United States, Series A, $25M raised) can offer investor introductions (inferred from public profile).
- ZymoChem is based in United States (North America): a landing pad on another continent, both ways.
- Same sector (Biotech & life sciences): peer learning on regulation, pricing and investors; Neumic Therapeutics Ltd works on University therapeutics spin-off (presumed neuroscience), ZymoChem on Synthetic biology – bio-based materials.
Score anatomy
Each segment is what one dimension adds, out of 100.
Score by goal
Dimension by dimension
Needs ↔ offers
12.5 / 25 pts
ZymoChem can help Neumic Therapeutics Ltd.
- Neumic Therapeutics Ltd likely needs funding — ZymoChem (United States, Series A, $25M raised) can offer investor introductions (inferred from public profile).
Market bridge
11.3 / 45 pts
Distant markets.
- ZymoChem is based in United States (North America): a landing pad on another continent, both ways.
Customer potential
0.0 / 10 pts
Neither side has a product on the market yet.
No supporting signal in the records.
Sector synergy
7.5 / 10 pts
Same sector: peers.
- Same sector (Biotech & life sciences): peer learning on regulation, pricing and investors; Neumic Therapeutics Ltd works on University therapeutics spin-off (presumed neuroscience), ZymoChem on Synthetic biology – bio-based materials.
Stage complementarity
4.5 / 10 pts
Weak stage signal.
- ZymoChem has raised about $25M — investor introductions are realistic.
- Stage not comparable (Undetermined / Series A).
How the score works
Each dimension gives a value between 0 and 1, multiplied by its weight; the compatibility is the sum (0–100). Weights for “Market entry”: Needs ↔ offers 25, Market bridge 45, Customer potential 10, Sector synergy 10, Stage complementarity 10. Declared needs and offers count fully; when a startup has declared nothing, a few needs/offers are inferred from its public profile (for example, no known traction ⇒ needs customers) and count at half value.
Potential blends compatibility (65%) with the mean global score of both startups (35%): 40/100 — high from 50, medium from 36.